Alveus Therapeutics has emerged from stealth with a $159.8 million Series A financing, positioning the clinical-stage biotech to take on one of global healthcare’s fastest-growing crises: obesity and metabolic disease.

 

The funding will drive Phase 2 clinical development of ALV-100, Alveus’ lead obesity candidate, and support multiple Investigational New Drug filings across its early-stage pipeline, including a highly selective amylin peptide agonist.

 

The oversized Series A round was led by New Rhein Healthcare Investors, Andera Partners, and Omega Funds, with backing from Sanofi Capital, Kurma Partners, Avego BioScience Capital, and other healthcare-focused investors. As part of the financing, Jan Van den Bossche of Andera Partners and Claudio Nessi of Omega Funds will join the company’s board.

 

“Obesity is one of the fastest-growing global healthcare challenges, and today’s therapies leave patients struggling to maintain weight loss over time,” said Raj Kannan, Chief Executive Officer of Alveus. 

 

“ALV-100 and our amylin-based pipeline are being developed to deliver durable efficacy with infrequent dosing, improved tolerability, and meaningfully better body-composition outcomes. With world-class investors and a team that has repeatedly brought metabolic medicines from concept to commercialization, Alveus is well positioned to lead the next wave of innovation in obesity therapeutics.”

 

ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor (GLP-1R) agonism. The program is designed to deliver sustained weight loss and long-term weight maintenance while improving tolerability—key shortcomings of today’s chronic obesity therapies.

 

Beyond ALV-100, Alveus is building a broad portfolio centered on selective amylin biology. The pipeline spans injectable and oral approaches aimed at improving durability, tolerability, and metabolic outcomes. ALV-200, a highly selective amylin receptor 3 (AMYR3) peptide agonist, has already advanced into IND-enabling studies, alongside additional oral small molecules and multifunctional candidates.

 

“New Rhein founded Alveus to combine a world class team, cutting-edge science, and an unwavering focus on long-term patient outcomes through the treatment of metabolic disorders. 

 

"With this Series A funding, we are accelerating the development of therapies addressing one of the largest health-economic burdens driven in part by the failure to sustain durable weight-loss or health outcomes,” said Nayan Parekh, Chairman of the Board of Alveus.

 

With preclinical and clinical operations anchored in the US and Denmark, Alveus is positioning itself as a globally integrated metabolic disease company from the outset.

 

“With preclinical and clinical operations anchored in the US and Denmark, Alveus combines global reach with executional excellence. We are proud to back a team that brings deep clinical insight and the ambition to make a lasting impact on global health while scaling innovation worldwide,” said Jan Van den Bossche, Partner at Andera Partners.

 

Claudio Nessi, Managing Director at Omega Funds added: “This Series A financing underscores our confidence in Alveus’ ability to set new standards of care in obesity and metabolic disease, which aligns with our mission to invest in innovation that make a lasting difference in patients’ lives.”